Using isolated rat kidneys perfused at controlled pressure, we examined a potential role of endothelium-derived relaxing factor (EDRF) in the pressure control of renin secretion. We found that stimulation of EDRF release by acetylcholine (1 ,tmol/liter) increased mean perfusate flow rates from 15.0±0.5 to 18.0±0.5 ml/min per g and average renin secretion rates from 3.5±0.5 to 16.0±2.0 ng angiotensin I/h per min per g at a perfusion pressure of 100 mmHg (mean±SEM, n = 6). Those effects ofacetylcholine were significantly reduced during inhibition of EDRF formation with NG-nitro-L-arginine (100 ,umol/ liter), but they were not affected with the cyclooxygenase inhibitor indomethacin (10 ,mol/liter).
Introduction
Since the first demonstration by Goldblatt and co-workers ( ), it has been well established that the intrarenal perfusion pres-sure is a main physiological control parameter for renin secretion from the kidneys. Renin that is released from the juxtaglomerular (JG)' cells by regulated exocytosis indirectly increases the blood pressure, and this effect is mediated by the vasoconstricting potency of angiotensin 11 (2) . Thus, pressure control of renin secretion is organized in form of a negative feedback loop with the amount of renin released from the kidneys correlating inversely with the intrarenal arterial pressure (2, 3) .
The renin producing JG cells are located in the wall of the afferent arterioles and a board of indirect evidence suggests that also this so-called "baroreceptor" is installed within the renal vasculature (4) (5) (6) . The subcellular signaling pathways, however, along which the renal artery pressure modulates renin secretion are not yet understood. One hypothesis existing about this baroreceptor mechanism suggests a direct effect of the intrarenal pressure on JG cells that is mediated by a pressure-dependent stretch of the JG cell membrane (6) . Experimental attempts to prove such a direct pressure effect on renin secretion from JG cells have produced controversial results.
While one group demonstrated changes ofrenin secretion from isolated perfused rabbit afferent arterioles in response to changes of the perfusion pressure (7), others did not report pressure related renin secretion in a similar preparation (8) . Nonetheless, these different findings may give some hints for the possible baroreceptor function; a pressure dependence of renin secretion, namely, was only found with a free-flow system allowing concomitant changes of flow in response to changes of the perfusion pressure (7), but not with a stop-flow system permitting modulation of the hydrostatic pressure only (8) . Those results could indicate that baroreceptor function requires flow through the afferent arterioles and therefore directing attention towards a possible role of endothelial cells in the pressure control of renin secretion.
Endothelial cells in fact have properties making them suitable for mechanotransduction. For instance they are equipped with ion channels that become activated during increased shear stress (9, 10) . Moreover, they release vasoactive autacoids such as endothelium-derived relaxing factor (EDRF), which is considered to be nitric oxide (NO) ( 11 ), in a flow-dependent fashion ( 12, 13) . Recent evidence suggests that the activation of shear stress-sensitive potassium channels is causally involved in the release of EDRF ( 14) . Furthermore, it has been demonstrated that endothelial cells can modulate renin secretion from isolated JG cells in primary culture ( 15) .
Nonetheless, the physiological role ofthe vascular endothelium in the control of renin secretion is not known. Also the having free access to commercial pellet chow and tap water were obtained from the local animal house and used throughout. Kidney perfusion was performed in a recycling system according to the technique of Schurek and Alt ( 18) with minor modifications as described previously ( 19) . In brief, the animals were anesthetized with 150 mg/kg of 5-ethyl-( 1'-methyl-propyl)-2-thio-barbituric acid (Inactin®; BYK Gulden, Konstanz, Germany). Volume loss during the preparation was substituted by intermittent injections of physiologic saline (-2.5 ml totally) via a catheter which was inserted into the jugular vein. After opening of the abdominal cavity by a midline incision the right kidney was exposed and placed in a thermostatically controlled metal chamber. The right ureter was cannulated with a small polypropylene tube ( PP-10) that was connected to a larger polyethylene catheter ( PE-50; Labotrade, Schonenbuch, Switzerland). After intravenous heparin injection (2 U/g Liquemin®; Roche, Basel, Switzerland) the aorta was clamped distal to the right renal artery and the large vessels branching off the abdominal aorta were ligated. A double-barreled cannula was inserted into the abdominal aorta and placed closely to the origin ofthe right renal artery. After ligation ofthe aorta proximal to the right renal artery the aortic clamp was quickly removed and perfusion was started in situ with an initial flow rate of 8 ml/min. The right kidney was excised and perfusion at constant pressure (100 mmHg) was established. To this end, the renal artery pressure was monitored through the inner part of the perfusion cannula (Statham transducer P 10 EZ: Gould, Spectramed Ltd., Coventry, UK) and the pressure signal was used for feedback control of a peristaltic pump. The perfusion circuit was closed by draining the renal venous effluent via a metal cannula back into a reservoir (200-220 ml). The basic perfusion medium, which was taken from the thermocontrolled (370C) reservoir, consisted ofa modified Krebs-Henseleit solution containing all physiologic amino acids except L-arginine in concentrations between 0.2 and 2.0 mM, and 8.7 mM glucose, 0.3 mM pyruvate, 2.0 mM L-lactate, 1.0 mM a-ketoglutarate, 1.0 mM L-malate, 6.0 mM urea, and 1 mU 100 ml vasopressin 8-lysine. The perfusate was supplemented with 6 g/ 100 ml BSA and with freshly washed human red blood cells ( 10±2% hematocrit). Ampicillin (3 mg/ 100 ml) and flucloxacillin (3 mg/ 100 ml) were added to inhibit possible bacterial contamination ofthe medium. To improve the functional preservation of the preparation, the perfusate was continuously dialysed against a 25-fold volume of the same composition but without containing erythrocytes and albumin. For oxygenation of the perfusion medium the dialysate was gassed with a 95% oxygen/5% carbon dioxide mixture. Perfusate flow rate was obtained from the revolutions of the peristaltic pump that was calibrated before and after each experiment. Renal flow rate and perfusion pressure were continuously monitored by a potentiometric recorder (Kipp & Zonen, Delft, Netherlands). Stock solutions ofthe drugs to be tested (see below) were dissolved in freshly prepared perfusate and infused into the arterial limb ofthe perfusion circuit directly before the kidneys (peristaltic pump 2132 Microperpex®; LKB, Bomma, Sweden) at 1% ofthe rate ofperfusate flow. For determination ofperfusate renin activity (pRA) aliquots (100 ,tl) were drawn from the arterial limb of the circulation and the renal venous effluent, respectively. The samples were centrifuged (4"C) at 1,500 g for 15 min (Sorvall RT 6000; Sorvall) and the supernatants were stored at -20'C until assayed for renin activity.
Determination ofrenin activity. Perfusate samples were incubated for 1.5 h at 370C with plasma of bilaterally nephrectomized male rats as renin substrate (20) . The generated angiotensin I was determined by radioimmunoassay (Medipro AG, Teufen, Switzerland).
Renin release. In a previous study performed with the same experimental model, we have found that renin is not inactivated during its passage through isolated perfused rat kidneys ( 19) . Therefore, renin secretory rates were calculated from the arteriovenous differences of perfusate renin activity and the corresponding renal flow rates.
Chemicals 
Results
Basal perfusate flow rates through the isolated rat kidneys perfused at 100 mmHg were 15.0±0.5 ml/min per g (mean±SEM; n = 15) and basal renin secretion rates were 3.5±0.5 ng Angiotensin I (AngI)/h per min per g (n = 15).
To obtain first evidence whether EDRF modulates renin secretion from whole kidneys at all, the hormone acetylcholine, which is a well-known activator of endothelial EDRF release (21), was added to the perfusate. Acetylcholine used in the concentration range between 10 nmol/liter and 1 ,umol/ liter caused a dose dependent increase of perfusate flow rate and also led to a graded stimulation of renin secretion at a perfusion pressure of 100 mmHg ( Fig. 1) . At a concentration of 1 gmol/liter acetylcholine, renin secretion rates were increased from the basal level of 3.5±0.5 to 16.0±2.0 ng AngI/h per min per g (n = 6). In parallel, urine flow rates increased from 71±14 ,l/min per g under control conditions to maximally 159±30 ,ul/min per g with 1 ,imol/liter acetylcholine (n =6).
NG-nitro-L-arginine (L-NNA; 100 pmol/liter), an inhibitor of EDRF formation (22) , significantly reduced the renal vascular relaxation and abolished the enhancement of renin secretion produced by acetylcholine ( 1 tmol/liter (Table II) and also renin secretion rates tended to decrease at 100 mmHg (Fig. 4) (Fig. 4) .
To test for the specificity of the effects obtained with L-NNA, we also investigated the influence of N0-nitro-D-arginine (D-NNA), a stereoisomer without inhibitory effect on EDRF formation (27) . D-NNA ( 100 ,gmol/liter) did not alter renal flow rates and even slightly improved the pressure response of renin secretion, while L-NNA ( 100 ,umol/liter) almost blunted the rise of renin release in the same kidneys (Fig.  5 ). For control, we examined as to whether L-NNA did also affect the renin stimulatory potency of isoproterenol, which activates renin secretion via cyclic AMP formation (2). As shown in Fig. 5 , isoproterenol used at a concentration of 10 nmol/liter, even in the presence of L-NNA and also during D-NNA administration, significantly increased renin secretion rates. Similar to L-NNA, L-NAME, and NMMA, two other inhibitors of EDRF formation, also significantly reduced renin release at a renal artery pressure of 40 mmHg (Table II) . On a molar basis, L-NNA and NMMA were more potent than L-NAME in decreasing renin secretion at a perfusion pressure of 40 mmHg (Table II) . Like L-NNA, L-NAME, and NMMA also significantly reduced perfusate flow rates to 13.0±0.5 and 12.5±0.5 ml/min per g (n = 3), respectively (Table II) . All three inhibitors of EDRF formation did not significantly change urine flow rates ( Table II) .
Assuming that a fall ofthe renal artery pressure requires the release of EDRF to become an effective stimulus for renin release, we tested as to whether pressure related renin secretion could be reestablished by mimicking NO release during inhibited EDRF formation. To this end, we examined pressure-dependent renin secretion in the combined presence of an EDRF inhibitor (L-NNA) and of an exogenous nitrate (sodium nitroprusside [SNP] ) that mimicks the action of EDRF. As shown in Fig. 6 , the addition ofSNP ( (Fig. 6) . Finally, we examined whether the pressure dependence of renin secretion was altered under conditions of stimulated EDRF release. To this end, renin secretion rates in the absence and in the presence of acetylcholine were determined in the same kidneys at perfusion pressures of 140, 100, and 40 mmHg. As shown in Fig. 7 , acetylcholine used at a concentration of 10 timol/liter significantly altered the relationship between perfusion pressure and renin secretion, in a way that it weakly increased renin release at high pressure and potently enhanced renin secretion at low perfusion pressure: At a renal artery pressure of 140 mmHg, acetylcholine (10 ,gmol/liter) did not significantly affect renin secretion rates, whereas a significant increase of renin release from 3.5±0.5 to 17.0±2.5 ng AngI/h per min per g (n = 3) was obtained at 100 mmHg (Fig.  7) . When the perfusion pressure was reduced to 40 mmHg, renin secretion rates increased to maximal values of 171±20 ng AngI /h per min per g (n = 3) in the presence of acetylcholine (Fig. 7) .
Discussion
The aim ofthis study was to investigate a possible involvement of EDRF in the pressure control of renin secretion from the kidneys, which is commonly referred to as the intrarenal baroreceptor mechanism of renin secretion. As an experimental model, we used an isolated rat kidney preparation perfused with a medium containing red blood cells, which is suitable to 19) . In particular, this model displays an inverse relationship between perfusion pressure and renin release (Fig. 7 , reference 17) in a fashion similar to the in vivo situation (28) . Moreover, we have recently demonstrated that the basic mechanisms of myogenic autoregulation of flow are preserved ( 17) and also characteristic signal transduction mechanisms such as angiotensin II induced inhibition or isoproterenol related stimulation of renin release are operating under those experimental conditions ( 17, 19) .
We found that acetylcholine, which activates the formation of endothelial autacoids such as EDRF also in renal vascular beds (21, 29), caused a dose dependent decrease in vascular resistance and an increase in renin secretion rates (Fig. 1) . Since these effects of acetylcholine were reversibly suppressed in the presence of an established inhibitor of EDRF formation (Fig. 2) , it appears most likely that the vasorelaxing and the renin stimulatory action of acetylcholine were both mediated by EDRF. In the same kidney preparations inhibition ofprostaglandin synthesis with indomethacin did not affect neither renal vascular relaxation nor the stimulation of renin release caused by acetylcholine (Fig. 3) and a possible involvement of prostacyclin in the actions of acetylcholine becomes therefore less likely (30) . A vasodilating effect of acetylcholine in the isolated perfused rat kidney is in keeping with previous studies (31, 32) as well as with a more general concept indicating a role of the vascular endothelium, particularly of EDRF, in the vasorelaxant action of acetylcholine (33) . Stimulation of renin release by acetylcholine has previously been reported for dogs (34) and turtles (35). A stimulatory effect of EDRF on renin secretion is also supported by our finding that inhibition of EDRF synthesis led to a decrease ofbasal renin release (Fig. 2 ). This observation is in good accordance with a recent study reporting that renin secretion from isolated rat kidneys perfused at a constant renal artery pressure of80 mmHg was significantly reduced with nitro-L-arginine, an inhibitor of EDRF formation (36) . A similar finding was made in anesthetized dogs in which blockade of NO synthase caused a decrease of plasma renin activity (37) . A stimulatory effect of EDRF on renin secretion is also supported by our recent cell coculture study with isolated juxtaglomerular cells and vascular endothelial cells ( 15) , but it is at variance with another in vitro study performed on kidney slices and suggesting an inhibitory action of EDRF on renin release ( 16) . In view ofthe latter discrepancy, it must be considered that acetylcholine induced stimulation of renin secretion as observed in this study was possibly related to changes of flow or was mediated by the macula densa mechanism rather than being caused by a direct stimulatory effect of EDRF on JG cells. However, since acetylcholine increased renin release predominantly at lower pressure values without affecting renal flow rates in this pressure range (Fig. 7) , the stimulation of
Nitro-L-Arginine 1001M renin secretion in response to acetylcholine was probably not mediated by parallel changes of flow. Moreover, acetylcholine also significantly increased urine flow rates at a perfusion pressure of 100 mmHg, and if there was an effect on glomerular filtration rate (GFR) at all, one should therefore expect that acetylcholine enhanced rather than decreased GFR (32) . As a consequence, the tubular sodium chloride delivery should if at all increase, thereby causing inhibition rather than a stimulation of renin secretion via the macula densa mechanism (38) . A major pathway along which EDRF exerts its cellular effects is via stimulation of soluble guanylate cyclase activity leading to a rise of intracellular cGMP levels (23) . The role of cGMP in the control ofrenin secretion is not yet unequivocally understood. Membrane permeable cGMP analogues such as 8-bromo-cGMP have been found either to inhibit renin release from kidney slices (39) and from cultured JG cells (39, 40) or to have no effect on renin secretion from kidney slices (41) and isolated perfused kidneys (42) . Also experiments with ANP, an activator of particulate guanylate cyclase (24) , have produced divergent results. Thus, ANP has been found to inhibit (39) or to stimulate (41) renin secretion in vitro from kidney slices and to decrease renin release from cultured JG cells (43) and in vivo upon systemic application (44) . Intrarenal infusion of ANP into conscious dogs (45) , as well as application of ANP into isolated perfused rat kidneys (46) , however, has been observed to stimulate renin release. The findings obtained in this study would suggest that an increase ofrenal cGMP levels has a stimulatory rather than an inhibitory effect on renin secretion. Whether this effect is due to a direct action ofcGMP in JG cells or indirectly mediated by other cells cannot be distinguished from our experiments with whole kidneys. It is also possible that the stimulatory effect of EDRF on renin secretion was not related to cGMP formation because there is accumulating evidence for biologic effects of EDRF/NO that are not linked to cGMP formation (47, 48) .
Irrespective of the molecular mechanism by which EDRF enhances renin secretion from whole kidneys, our findings also show that the enhancement ofrenin release from the kidneys in response to a reduction of the perfusion pressure was almost blunted in the presence of drugs (Fig. 4, Table II ), that are commonly considered to inhibit EDRF formation ( 13, 22, 49, 50) . The following lines of evidence support the specific action of these inhibitors of EDRF synthesis on renin release: Firstly, the effects ofL-NNA and related compounds could partially be reversed by the addition of higher concentrations of L-arginine (Figs. 2 and 4) which is an established maneuver to restore inhibited EDRF formation (49) . Secondly, nitro-D-arginine, a stereoisomer of nitroarginine, which is presumed not to block EDRF synthesis (27) , also did not attenuate the pressure dependence of renin secretion (Fig. 5) . Thirdly, the stimulatory effect of isoproterenol, which directly enhances renin secretion by increasing cellular cAMP levels (2) was not influenced during inhibition of EDRF formation (Fig. 5) . Finally, substitution of EDRF by an artificial analogue, such as SNP reestablished the pressure dependence of renin secretion, even in the presence of inhibitors of EDRF synthesis (Fig. 6) .
Taken together, we infer from our findings that EDRF is a stimulatory signal for renin secretion in the kidneys, and we suggest that tonically released EDRF accounts for the rise of renin secretion caused by a fall of the perfusion pressure.
The question arises as to whether the typical inverse relationship between renin secretion and renal artery pressure results from a pressure-dependent formation of EDRF, in a way that EDRF release is low at high pressure and high at low pressure. Another possibility would be that the release of EDRF is less pressure dependent, but that the stimulatory effect of EDRF on renin secretion is counterbalanced by a second pressure related process. We attempted to distinguish between both possibilities by assaying cGMP in the venous renal effluent as an indirect measure for renal EDRF activity. However, cGMP concentrations in the perfusate were below the detection limit of the radioimmunoassay used (< 25 fmol/ml), thus allowing no information about pressure dependent formation of EDRF in the kidneys.
Nonetheless, we think that there are two lines of indirect evidence suggesting that the effect of EDRF on renin secretion from JG cells rather than the formation of EDRF itself was controlled by the perfusion pressure. Thus, acetylcholine produced a potent EDRF dependent vasodilation at 100 mmHg (Fig. 2) , indicating that the release of higher quantities of EDRF can principally occur in this pressure range. At the same time there was only a relatively weak EDRF dependent stimulation ofrenin secretion at 100 mmHg, but a powerful increase of renin release with decreasing perfusion pressure (Fig. 7) . Similarly, mimicking the effect of EDRF on soluble guanylate cyclase activity with SNP markedly decreased vascular resistance but only weakly stimulated renin secretion at 100 mmHg (Fig.  6 ). Similar to acetylcholine the stimulatory effect of SNP on renin secretion became enhanced by lowering the perfusion pressure to 40 mmHg (Fig. 6) .
Taken together, our findings are compatible with the concept that the baroreceptor mechanism controlling renin secretion consists of at least two components. A tonical stimulatory one provided by the continuous release of EDRF from the vascular endothelium or from other cellular structures of the kidney. And a second inhibitory one, that is directly related to the perfusion pressure and that is enough potent to neutralize the stimulatory influence of EDRF at higher pressure values.
